Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal
Altimmune Inc (NASDAQ:ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty…
Altimmune Stock Is Tanking: What’s Going On?
Altimmune Inc (NASDAQ: ALT) shares are falling Wednesday morning. The company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50
HC Wainwright & Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $25 to $50.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session
Gainers
Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.
B. Riley Securities Maintains Buy Rating for Altimmune: Here’s What You Need To Know
B. Riley Securities has decided to maintain its Buy rating of Altimmune (NASDAQ:ALT) and raise its price target from $21.00 to $26.00.
Shares of Altimmune are trading up 23.53% over the last 24 hours, at $17.01 per share.
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
Altimmune, Inc. (NASDAQ: ALT) jumped 28% to $17.64. B. Riley Securities maintained Altimmune with a Buy and raised the price target from $21 to $26.
B. Riley Securities Maintains Buy on Altimmune, Raises Price Target to $26
B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $21 to $26.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.